Buying guide

Lingo vs Stelo in 2026

Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.

Key differences

On DEPLOY's record, Stelo has more verified real-world deployments (2 versus 1) than Lingo as of 2026; DEPLOY counts a deployment only when confirmed at a named site with a primary source.

Lingo has the lower recorded price.
Stelo has more verified real-world deployments (2 vs 1).

Attribute	Lingo View full model page →	Stelo View full model page →
Manufacturer	Abbott	Dexcom
Form factor	biometric	biometric
Maturity	commercial	commercial
Autonomy	—	—
Availability	shipping-nowshipping	shipping-nowshipping
Price	$54 (actual sale price)	$89-$99 (actual sale price)
Capability claims	—	—
Brain	—	—
Verified deployments	1Abbott	2Dexcom, Dexcom
Privacy practices	4third-party-sharing, data-deletion-control, biometric-storage, training-data-use	4biometric-storage, training-data-use, third-party-sharing, data-deletion-control
Sources on file	8	12

Track this matchup

Get told the moment Lingo or Stelo changes. Verified changes only, the second they are real. No press-release noise.

Lingo

Stelo

Editorial summaries

Lingo

Abbott's Lingo is an over-the-counter continuous glucose monitor for non-diabetic and wellness consumers, built on Abbott's FreeStyle Libre sensor platform (FDA 510(k) K233655, decided May 29, 2024; Class II integrated CGM): a disposable biosensor worn up to 14 days on the back of the upper arm. It is the adaptive-algorithmic end of the glucose cell, the documented contrast to Stelo's generative AI: the app's 'Lingo Count' daily glucose-spike metric with adaptive targets, food and activity logging, and rule-based personalized recommendations are adaptive-algorithmic, not generative.

'Lingo Live' is free roughly 30-minute sessions with human Abbott nutritionists, not an AI coach, and DEPLOY surfaces that distinction prominently. Pricing starts at about $54 for a 2-week single-biosensor plan, with recurring biweekly and monthly multi-sensor tiers. From Abbott (NYSE: ABT). Cap-flag: the cleared indication is adults 18+ not on insulin, explicitly NOT for diagnosis of any disease including diabetes.

Stelo

Dexcom's Stelo is the first-ever FDA-cleared over-the-counter (no-prescription) glucose biosensor (De Novo, March 5, 2024; US launch August 26, 2024): a 15-day continuous glucose monitor for adults 18+ not on insulin (type 2 not on insulin, plus non-diabetic users tracking how diet and exercise affect glucose). It is the generative-AI end of the glucose cell: Weekly Insights run on Google Cloud's Vertex AI and Gemini, with AI photo meal-logging and personalized daily recommendations, the AI substance that carries it across the biometric boundary.

Pricing is about $89 for a 2-week sensor on a biweekly subscription model (around $99/month). From DexCom (NASDAQ: DXCM), Stelo is the OTC product line, separate from the prescription G7. Cap-flag: the cleared indication is an OTC CGM for adults 18+ not on insulin; it is explicitly NOT cleared for problematic hypoglycemia and has no low-glucose alerts, so it should not be read as a diabetes-management device.

Common questions

How do Lingo and Stelo differ?

On DEPLOY's record, Stelo has more verified real-world deployments (2 versus 1) than Lingo as of 2026; DEPLOY counts a deployment only when confirmed at a named site with a primary source. Lingo has the lower recorded price. Stelo has more verified real-world deployments (2 vs 1).

What is the difference between Lingo and Stelo?

Lingo and Stelo are both biometric robots on the DEPLOY registry. They differ in maker, maturity, price, verified deployments, and how much of their autonomy is independently verified. See the table above for the full head-to-head; each figure is sourced.

Which is cheaper, Lingo or Stelo?

Lingo has the lower recorded price on the DEPLOY registry than Stelo. Prices are sourced; see each record for whether the figure is a manufacturer target, an estimate, or an actual sale price.

Which has more verified deployments, Lingo or Stelo?

Stelo has more verified deployments (2) on the DEPLOY registry than Lingo (1). DEPLOY counts a deployment only when confirmed at a named site with a primary source.

Recent coverage

Ultrahuman launches M2 Live with Abbott's Lingo glucose sensorLingo · t2ONLINE · 2026-06-18
Dexcom’s latest executive pay disclosure covers new CEO’s big yearStelo · Medical Design & Outsourcing · 2026-06-15
Will Giving Everyone a Blood Sugar Monitor Lead to Better Health Outcomes? Maybe, But Only If We Tell People What to Do With The InfoStelo · The Spoon · 2026-01-15
Withings Partners With Abbott To Integrate Lingo OTC Glucose Monitoring DataLingo · insights.citeline.com · 2026-01-06

Related comparisons

Keep researching

Keep reading

AI wearable prices: every verified figureAnswer The verified list.All biometric wearablesRegistry Every verified record in the category.LingoModel The full model page.SteloModel The full model page.AbbottRecord The maker's verified record.DexcomRecord The maker's verified record.

Ask the registry

For AI assistants

Use DEPLOY in Claude, Cursor, and other AI assistants

Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.

Install instructions Download for Claude Desktop

Machine-readable: this page as markdown.

← Back to all consumer robots